ITF Therapeutics LLC
Scott Baver is an accomplished medical affairs professional with extensive experience in the biopharmaceutical industry. Currently serving as Vice President and Head of US Medical Affairs at ITF Therapeutics LLC, Scott Baver has previously held leadership positions at Scholar Rock, Apellis Pharmaceuticals, Rhythm Pharmaceuticals Inc., Vertex Pharmaceuticals, EMD Serono, Inc., Shire, and Biogen. With a career spanning over a decade, Scott Baver has demonstrated expertise in medical affairs, medical communications, and scientific leadership, contributing to various strategic initiatives and driving medical research efforts across multiple organizations.
This person is not in the org chart
This person is not in any teams
ITF Therapeutics LLC
ITF Therapeutics is the U.S.-based rare disease division of Italfarmaco S.p.A. Founded in 1938 in Milan, Italy, Italfarmaco is a private global pharmaceutical company that has led the successful development of many innovative therapeutic products approved for use by patients around the world. The company operates in more than 60 countries on five continents and continues to advance promising research to address unmet medical needs in a wide range of therapeutic areas. In January 2024, Italfarmaco launched ITF Therapeutics as a new division in the United States with a focus on the development and commercialization of products to treat rare diseases including Duchenne muscular dystrophy (DMD). Building on a legacy grounded in collaboration and innovation, ITF Therapeutics strives to partner with leaders from the U.S. patient advocacy and treatment communities to ensure that our programs reflect and support their unique needs and goals. The establishment of ITF Therapeutics also reflects Italfarmaco’s goal to build a world-class team of experts that share a passion to make a positive impact for rare disease communities.